Hepion Pharma stockholders elect all director nominees, ratify BDO, approve equity plan, pass say-on-pay

Hepion Pharmaceuticals, Inc.

All seven director nominees elected; votes For ranged from 15.7M (Jacob) to 20.7M (Wijngaard).
Ratification of BDO USA as auditors passed with 32.5M For, 8.3M Against, 0.8M abstain.
2023 Omnibus Equity Incentive Plan approved with 14.4M For, 12.0M Against, 0.3M abstain.
Advisory say-on-pay proposal passed with 14.2M For, 12.2M Against, 0.4M abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Hepion Pharmaceuticals, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company's named executive officers at the 2023-06-22 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

To approve, on an advisory basis, the compensation of the Company’s named executive officers, referred to as “say-on-pay.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Hepion Pharmaceuticals, Inc. shareholders approved Election of seven directors at the 2023-06-22 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

To elect the seven (7) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified including Gary S. Jacob, Robert Foster, John P. Brancaccio, Timothy Block, Peter Wijngaard, Anand Reddi and Kaouthar Lbiati.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of BDO USA, LLP as the Company's independent auditors for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

To ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Hepion Pharmaceuticals, Inc. shareholders approved Approve the Company's 2023 Omnibus Equity Incentive Plan at the 2023-06-22 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

To approve the Company’s 2023 Omnibus Equity Incentive Plan.

View on SEC.gov

560 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-073836

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.